99mTc-MIBI SPECT and multidrug resistance-related protein in patients with ovarian cancer

卵巢癌患者的 99mTc-MIBI SPECT 及多药耐药相关蛋白

• 批准号: 23591806
• 负责人: KURATA Seiji
• 金额: $ 3.24万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591806/
• 关键词: 卵巣癌; 核医学; 薬剤耐性; 99mTc-MIBI; 婦人科癌; 核医学トレーサー; 腫瘍核医学

The aim of this study was to evaluate the useful of 99mTc-MIBI SPECT for functional imaging of MDR-related protein: Thirteen women with a clinical suspicion of ovarian cancer were prospective studied. After intravenous injection of 740MBq 99mTc-MIBI, SPECT imaging at 10 minutes and 2 hours was performed. On the SPECT images, tumor uptake ratio of both early and delayed images, and washout rate of 99mTc-MIBI were calculated. The expression of MDR protein was assessed in surgically excised tumors. The immunohistochemical staining was performed. Six primary ovarian cancers were proven by histopathological examination. Five of the six ovarian cancers were positive on both early and delayed images with 99mTc-MIBI SPECT. The expression of MDR-related protein was found in all tumors. The washout rate of 99mTc-MIBI showed a significant positive correlation with YB-1 expression. Early tumor uptake ratio showed a significant positive correlation with Bax expression.

本研究的目的是评估99 mTc-MIBI SPECT对MDR相关蛋白功能成像的有用性：前瞻性研究了13名临床怀疑卵巢癌的女性。静脉注射99 mTc-MIBI 740 MBq后，分别于10 min和2 h行SPECT显像。在SPECT显像上，计算肿瘤早期显像和延迟显像的摄取率及99 mTc-MIBI的洗脱率。在手术切除的肿瘤中评估MDR蛋白的表达。免疫组化染色。6例原发性卵巢癌经组织病理学检查证实。6例卵巢癌中有5例在99 mTc-MIBI SPECT早期和延迟显像上均呈阳性。MDR相关蛋白在所有肿瘤中均有表达。99 mTc-MIBI洗脱率与YB-1表达呈显著正相关。早期肿瘤摄取率与Bax表达呈显著正相关。

项目成果

Comparison between endoscopic macroscopic classification and F-18 FDG-PET findings in gastric MALT lymphoma patients

胃MALT淋巴瘤患者内镜宏观分类与F-18 FDG-PET表现的比较

• 发表时间: 2012
• 期刊: Clinical Nuclear Medicine
• 影响因子: 10.6
• 作者: Yasumitsu Hirose;Naohumi Hayabuchi;et al
• 通讯作者: et al